Alphatec Earnings Call Highlights Growth Amid EOS Hurdles

Alphatec ((ATEC)) has held its Q1 earnings call. Read on for the main highlights of the call.

Alphatec’s latest earnings call struck an overall upbeat tone, with management highlighting double‑digit revenue growth, accelerating surgeon adoption, expanding margins, and sharply higher adjusted EBITDA. While execution hiccups around the EOS imaging platform and mix‑driven revenue‑per‑case pressure weighed on the quarter, the company argued that scale, profitability, and strategic positioning remain firmly on track.

Robust Revenue Growth Anchored by Surgical Business

Alphatec reported total Q1 revenue of $192 million, up 14% year over year, underscoring continued demand momentum across its spine portfolio. Surgical revenue was the standout, rising 17% to $178 million and reinforcing the company’s position that procedure volumes, not pricing, are driving the current growth cycle.

Surgeon Adoption and Case Volumes Drive Scale

Procedural metrics underscored the strength of the franchise, with case volumes up 21% year over year, pointing to broad‑based utilization gains. New surgeon users increased 23%, signaling durable adoption that can support multi‑year, volume‑led growth as those surgeons ramp their procedure counts over time.

Adjusted EBITDA Nearly Doubles as Profitability Expands

Profitability improved sharply, with adjusted EBITDA reaching $21 million in Q1, or 11% of revenue, up 97% from the prior year. Management highlighted roughly 45% drop‑through on incremental revenue and noted that trailing twelve‑month adjusted EBITDA has now surpassed $100 million, marking a key scale milestone.

Higher Margins and Clear Operating Leverage

Gross margin climbed to 71.6%, an improvement of more than 120 basis points year over year, reflecting product mix and scale benefits. Operating expenses increased about 6%, well below revenue growth, demonstrating tangible operating leverage as the company grows into its commercial and R&D investments.

Procedure Pricing Holds Firm Across Core Segments

Despite mix pressure at the consolidated level, core procedural average selling prices held firm or improved. Lateral procedure ASPs rose 2% year over year, ALIF pricing increased 4%, and cervical procedures posted an 8% ASP gain, underscoring pricing resilience where Alphatec has strong differentiation.

Solid Cash Generation and Liquidity Foundation

The balance sheet remains supported by approximately $140 million of cash at quarter‑end and positive operating cash flow for the fourth straight quarter. Free cash outflow of about $11 million in Q1 fell within expectations, and management reiterated full‑year free cash flow of at least $20 million, suggesting improving cash efficiency as growth investments normalize.

Refinancing Sharpens Capital Structure and Cuts Interest

Alphatec closed a new Term Loan A and revolving credit facility that extend debt maturities to 2031 and lower borrowing costs. The structure, priced at SOFR plus 275 basis points, is expected to trim annual interest expense by more than $6 million and could save up to roughly $35 million over the life of the facility, freeing capacity for growth initiatives.

EOS Platform Adoption Builds Long‑Term Optionality

The company’s EOS imaging ecosystem continued to deepen its footprint, with the global installed base up 7% year over year and the higher‑end EOS Edge installed base up 39%. EOS Insight accounts more than doubled, and management cited meaningful implant pull‑through, with surgeons typically driving about a 30% revenue lift after adopting the software‑driven planning platform.

Execution Missteps Pressure EOS Revenue

In contrast to adoption trends, EOS revenue fell to $14 million in Q1, down $3 million from the prior year, as deliveries and installations lagged plan. Management blamed construction and buildout delays at hospital sites and other timing issues, which pushed out system revenue recognition and created pronounced quarter‑to‑quarter lumpiness in the EOS line.

Sequential Surgical Slowdown Raises Near‑Term Questions

Surgical revenue declined 6% sequentially, a steeper drop than the company typically sees between quarters and partly tied to softer demand late in March. Management also pointed to lower revenue‑per‑procedure contribution in the period, suggesting that even as volumes grow, mix and attachment rates can cause short‑term volatility in reported surgical revenue.

Revenue per Case Hit by Mix and Attach Rates

Overall revenue per case fell about 3% year over year, driven by a greater share of cervical procedures and faster international growth, both of which carry lower per‑case economics. A weaker‑than‑planned biologics attachment also dragged on revenue per case, highlighting an area where Alphatec sees room to improve cross‑selling execution.

EOS Outlook Trimmed but Long‑Term View Intact

Reflecting the installation challenges, management reset its FY 2026 EOS revenue expectation to approximately $77 million, tempering near‑term growth assumptions for the imaging platform. The company nonetheless reiterated its conviction in the long‑term opportunity for EOS and Insight to drive implant pull‑through and deeper integration with spine surgeons.

Biologics Underperformance Adds to Mix Headwinds

The biologics attachment rate landed at roughly 38% in the quarter and fell short of internal expectations, weighing on both revenue per case and overall mix. Management now anticipates only modest near‑term improvement, implying that biologics will remain a tactical focus area but not a major driver of upside over the next few quarters.

Heavy Inventory and Instrument Spend Uses Cash

Alphatec invested about $33 million in inventory and instruments during Q1 to support growth in new surgeons and procedures across its expanding footprint. Instrument spend rose faster year over year than doctor growth, temporarily increasing working capital needs, but management framed this as a deliberate, time‑bound investment to underpin future case volume.

Quarter Fell Short of Internal Hopes

Management acknowledged that Q1 results came in below internal expectations, primarily due to the EOS shortfall and several one‑off execution items. Weather‑related and shipping disruptions, along with installation timing issues, were cited as additional headwinds that masked otherwise robust underlying surgical trends and margin progress.

Guidance Reinforces Confidence in Multi‑Year Growth Path

Despite near‑term growing pains, Alphatec reaffirmed its full‑year 2026 outlook, calling for roughly $882 million in total revenue, up about 15% year over year, including about $805 million in surgical revenue, or 17% growth. The company also maintained guidance for around $134 million in adjusted EBITDA at a 15% margin, a drop‑through of roughly 35%, and at least $20 million in free cash flow, underscoring management’s confidence in sustained scale and profitability gains.

Alphatec’s earnings call painted a picture of a company balancing strong surgical growth and improving profitability against operational missteps in its EOS platform and mix‑related revenue pressure. For investors, the story remains one of rising scale, better margins, and strategic capital moves, with execution on installations and biologics seen as key swing factors for the stock over the coming quarters.